Prelude Therapeutics Incorporated (PRLD)
Automate Your Wheel Strategy on PRLD
With Tiblio's Option Bot, you can configure your own wheel strategy including PRLD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PRLD
- Rev/Share 0.0921
- Book/Share 1.3579
- PB 0.668
- Debt/Equity 0.1737
- CurrentRatio 5.1753
- ROIC -1.1277
- MktCap 51215302.0
- FreeCF/Share -1.393
- PFCF -0.4838
- PE -0.5392
- Debt/Assets 0.1269
- DivYield 0
- ROE -0.8918
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | PRLD | H.C. Wainwright | Neutral | Buy | -- | $5 | Sept. 19, 2024 |
News
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.
Read More
Prelude Therapeutics to Participate in Citizens Life Sciences Conference
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking place in New York on May 7, 2025.
Read More
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Prelude Therapeutics (PRLD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
About Prelude Therapeutics Incorporated (PRLD)
- IPO Date 2020-09-25
- Website https://www.preludetx.com
- Industry Biotechnology
- CEO Dr. Krishna Vaddi D.V.M., Ph.D.
- Employees 131